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Abstract
Turner syndrome, a congenital condition that affects ∼1/2,500 births, results from absence or 
structural alteration of the second sex chromosome. There has been substantial effort by numerous 
clinical and genetic research groups to delineate the clinical, pathophysiological, cytogenetic, and 
molecular features of this multisystem condition. Questions about the molecular-genetic and 
biological basis of many of the clinical features remain unanswered, and health care providers and 
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families seek improved care for affected individuals. The inaugural “Turner Resource Network 
(TRN) Symposium” brought together individuals with Turner syndrome and their families, 
advocacy group leaders, clinicians, basic scientists, physician-scientists, trainees and other 
stakeholders with interest in the well-being of individuals and families living with the condition. 
The goal of this symposium was to establish a structure for a TRN that will be a patient-powered 
organization involving those living with Turner syndrome, their families, clinicians, and scientists. 
The TRN will identify basic and clinical questions that might be answered with registries, clinical 
trials, or through bench research to promote and advocate for best practices and improved care for 
individuals with Turner syndrome. The symposium concluded with the consensus that two 
rationales justify the creation of a TRN:
1. inadequate attention has been paid to the health and psychosocial issues facing girls and 
women who live with Turner syndrome;
2. investigations into the susceptibility to common disorders such as cardiovascular or 
autoimmune diseases caused by sex chromosome deficiencies will increase 
understanding of disease susceptibilities in the general population.
Keywords
monosomy X; Turner syndrome; women; congenital heart disease; genetics; neurodevelopment; 
chromosome; sex chromosomes; women's health; quality of life
Introduction
The First Turner Resource Network (TRN) Symposium was held July 13–14, 2014 in 
Jacksonville, Florida in conjunction with the 27th Annual Conference of the Turner 
Syndrome Society of the United States (TSSUS). The symposium brought together adults 
and children with Turner syndrome, their families, and representatives from other Turner 
syndrome support and advocacy groups, including the Turner Syndrome Foundation and the 
Turner Syndrome Global Alliance, clinicians and basic scientists, trainees and other 
stakeholders. A major theme of the gathering was to highlight the considerable 
accomplishment of the Turner syndrome community itself. Participants included women 
living with Turner syndrome from all walks of life including mothers, daughters, lawyers, 
judges, administrators, pediatricians, internists, endocrinologists, clinical geneticists, and 
psychologists among others. By virtue of the free exchange of ideas that occurred during the 
two-day event, these advocates challenged and engaged the entire group of more than 200 
participants.
Prior to the meeting, a survey developed by the Advocacy Committee of the TRN was 
distributed to the members of the Turner Syndrome Society of the United States, and 
gathered responses from more than 700 individuals. The survey results were a focal point of 
the symposium and will direct the activities of the TRN going forward.
The symposium itself had three closely interrelated goals:
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1. To identify the major health policy issues facing girls and women living with 
Turner syndrome (Session I, “Health Care Policy and Health Care Delivery for TS 
Patients”);
2. To review basic and clinical questions that might be answered by either bench 
research, clinical trials, clinical datasets or registries (Session II, “Turner Science: 
From Genotype to Phenotype”); and
3. To discuss a strategy for how a national network of regional Turner syndrome 
resource centers (the TRN) will be organized (“Session III: The TRN roadmap”).
Turner syndrome is a rare heterogeneous condition caused by absence of all or part of the 
second sex chromosome in at least a proportion of the body's cells in individuals with a 
female phenotype. How underlying mechanisms related to X monosomy at the level of 
individual tissues bring about the varied phenotypic features remains largely unknown. 
Importantly, the impact of the genetic deficiencies on numerous body systems creates 
interrelated challenges for those who live with Turner syndrome that society and the U.S. 
health care system in general have barely begun to address. These problems include ovarian 
insufficiency, infertility, and problems with the lymphatic system. In addition, there is an 
increased prevalence of numerous common conditions that affect the general public, 
including cardiovascular disease, hypertension, stroke, and autoimmune dysfunction. Many 
girls and women with Turner syndrome have to deal with chronic and recurrent otitis media, 
conductive and sensorineural hearing impairment, orthopedic and dental issues and some 
also must address neuropsychological problems that include learning disability, executive 
function dysregulation and specific areas of cognitive and social challenge. Compelling 
epidemiological evidence indicates a threefold higher death rate (primarily due to 
cardiovascular causes) in women with Turner syndrome compared to the risk for the general 
female population at the equivalent age (Fig. 1) [Schoemaker et al., 2008].
Two rationales have energized the stakeholders to make the TRN initiative a success:
1. Unacceptable levels of morbidity/mortality and the lack of access comprehensive 
health care among girls and women living with Turner syndrome must be 
addressed, and
2. Susceptibility to common conditions caused by deficiencies of X/Y-chromosomal 
genes will lead to an understanding of disease susceptibilities in the general 
population.
This novel second rationale was introduced during the first morning of the symposium by 
Dr. David C. Page, the Director of the Whitehead Institute and a Professor at the 
Massachusetts Institute of Technology. A summary of Dr. Page's comments provided here is 
followed by a summary of the meeting presentations (Section II), speakers' abstracts 
(Section III) and a TRN roadmap (Section IV, breakout sessions).
How Understanding Turner Syndrome Will Teach us About Health and Disease in the 
General Population. David C. Page, MD
The question of Turner syndrome's origin is far more complex than it may seem, and 
answering it will lead us to a broader understanding of the role of the sex chromosomes in 
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health and disease. Turner syndrome was equated with monosomy X in 1959, and to this 
day, it is still considered to be a chromosomal anomaly. However, when Henry Turner and 
Otto Ullrich first defined the disorder in the 1930s, they were not describing a chromosomal 
anomaly but a clinical phenotype. To fully understand the interplay between this 
chromosomal anomaly and the complex Turner phenotype, we need to disentangle several 
related questions. We could begin by asking: What causes monosomy X? When during sex 
cell or embryonic development does the loss of the second sex chromosome occur? We now 
know that most females with Turner syndrome have a chromosome anomaly in only a subset 
of their cells and tissues. Moreover, not everybody with Turner syndrome has monosomy X. 
The diagnosis actually refers to a grab bag of clinical anomalies in combination with the 
absence of all or part of a second sex chromosome, either the X or the Y. We are now in the 
position to ask a different question: How does the absence of all or part of a second sex 
chromosome result in the clinical features of the syndrome described by Henry Turner and 
Otto Ullrich?
Asking this question creates a connection between the study of Turner syndrome and 
broader research on how genetic and molecular differences between males and females lead 
to differences in health and disease. In 1993, my laboratory colleagues and I, hypothesized 
that the phenotypic features of Turner syndrome result from having just a single dose (rather 
than a double dose) of genes that are common to the X and Y chromosomes and that escape 
X inactivation [Watanabe et al., 1993; Zinn et al., 1993]. During most of the two decades 
since, and indeed until very recently, progress in this area had been slow; even today, studies 
of the sex chromosomes lag behind the rest of the genome. Most notably, researchers 
pursuing genetic understanding through genome wide association studies (GWAS) had 
mostly excluded the X and Y chromosomes from their investigations, largely for technical 
reasons.
I envision an opportunity for the sex chromosomes to return to a place of prominence in our 
understanding of health and disease. When you compare an XY male to an XX female, they 
are only 98.5 percent the same in their genomes: 15 times the genetic difference when 
comparing two males or two females. These differences may manifest themselves 
phenotypically. For example, the incidence of rheumatoid arthritis is 2–3 times greater in 
women than in men. Five boys are affected by autism spectrum disorder for every girl who 
is diagnosed. The ratio of females to males diagnosed with lupus is six to one. In the case of 
dilated cardiomyopathy, affected men tend to die about 10 years earlier than affected 
women. In none of these cases is the disease related to the reproductive tract, but should 
ultimately be accounted for by sex chromosomal differences between XY males and XX 
females.
To understand our sex chromosomes more deeply, we must turn to evolution. The human X 
and Y chromosomes evolved from an identical pair of autosomes. The X chromosome has 
retained nearly all of the 649 genes present on the ancestral autosomes, while the Y 
chromosome has retained only 17. The 17 survivors, shared by both the X and Y 
chromosomes today, turn out to be involved in regulating the activity of other genes 
throughout our entire genome [Bellott et al., 2014]. We have strong evidence that 12 of 
these genes are needed in two copies—one in each of the two sex chromosomes present in 
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XX or XY cells—to function properly. It is likely that Turner syndrome patients, lacking a 
second sex chromosome, manifest disease because of the haploinsufficency of these 12 
genes. We should be able to account for the genetic varieties of Turner syndrome by 
understanding these genes shared by the X and Y chromosomes. In addition, an 
understanding of the genetic basis of disease susceptibility caused by deficiencies of the 
second sex chromosome will help us to understand the panoply of differences between men 
and women in health and disease. In sum, I suggest that we forge strong links between 
research on Turner syndrome and research on sex differences in disease generally.
Short Summaries of Meeting Presentations (Abstracts from Each 
Presentation are Provided Below and an eBook Containing the Entire 
Proceedings is Planned for Publication Summer 2015)
Dr. Stephen D. Chernausek discussed the future of health care for patients with Turner 
syndrome and the role of patient advocates, doctors, and the performance of translational 
research in the current environment. He focused on both expanding the manner in which 
health care could be delivered across the spectrum of age, and the heterogeneity of clinical 
issues that girls and women face. Dr. Carolyn Bondy reviewed the most current clinical 
guidelines for the care of girls and women with Turner syndrome [Bondy and Turner 
Syndrome Study, 2007] with the future goal of updating these guidelines, especially in the 
area of cardiovascular imaging and prenatal diagnosis. Dr. David Sandberg focused on 
health care access and the barriers in the health care system, particularly in the areas of 
behavioral health and the transition from pediatric to adult care [Conway 2009; Devernay et 
al., 2009; American Academy of Pediatrics, 2011; Crowley et al., 2011]. Dr. Gary A. 
Lorigan presented the results of a survey that was submitted to the TSSUS membership. Of 
4,147 potential respondents Dr. Lorigan received 385 responses from women living with 
Turner syndrome and 417 responses from parents/guardians. Their concerns included social 
and psychological issues as well as educational and vocational challenges. The major 
medical issues facing Turner syndrome patients included cardiovascular, endocrinological, 
and hearing problems. Dr. Philippe B. Backeljauw presented the results of the work from a 
professional panel that discussed the important components of a regional Turner resource 
center and the logistics of how such centers might be structured with larger more established 
programs collaborating with local clinics. Dr. Nelly Mauras presented her study related to 
the type and route of administration of estrogen replacement in girls with Turner syndrome 
[Torres-Santiago et al., 2013] as both a model of the type of research that could be done by 
the TRN, as well as how the data might influence guidelines for future care. Dr. Rebecca 
Knickmeyer presented evidence that girls and women with Turner syndrome have critical 
differences in key components of neural circuits for social cognition and working memory 
[Knickmeyer, 2012]. Dr. David Hong pointed out that while intelligence is normal, and 
verbal skills are enhanced for those living with Turner syndrome, visual spatial skills, 
executive function, arithmetic, and social cognition are at risk [Green et al., 2014]. Dr. 
Siddharth K. Prakash presented the results of a genome-wide association study describing 
preliminary evidence that modifier genes are present on chromosomes 4, 18, and 22 that 
may account for the high frequency of bicuspid aortic valve in Turner syndrome. Dr. 
Carolyn Bondy presented a large body of work from the National Institute of Child Health 
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and Human Development natural history study which included nearly 500 girls and women 
with Turner syndrome, focusing on the congenital anatomic findings. There appear to be 
biological differences in rates of atherosclerotic heart disease between those women who 
carry a maternal X chromosome (increased risk) versus those with a paternal X chromosome 
(lower risk) [Abd-Elmoniem et al., 2014]. Dr. Paul Kruszka described work being done at 
the Medical Genetics Branch of the National Institutes of Health on the genetic 
underpinnings of congenital heart disease in Turner syndrome, including whole exome 
sequencing studies and the development of an animal model. Dr. Victoria Pemberton 
discussed the challenges of conducting human-based research in rare conditions.
Networks or “Collaboratories,” composed of multiple research centers, will be necessary to 
recruit adequate numbers of subjects for future research. Dr. David Cole discussed the 
challenges to funding an organization like the TRN in an era of diminished federal 
investment in medical science. A key to the TRN's success will be empowerment through 
the patients living with Turner syndrome and their families. An important strength of the 
TRN steering committee will be the direct participation of all the stakeholders, with patient 
advocates taking the lead.
Speakers' Abstracts
Health Care Policy and Health Care Delivery for TS Patients
The future of health care in the USA: Patient advocates, doctors, and 
translational research. Steven D. Chernausek, MD—Henry Turner, an internist, 
described the clinical features of Turner syndrome in 1938. Initially, medical care for 
patients with Turner syndrome focused on making the diagnosis, detecting associated 
anomalies, treating hypogonadism, and maximizing final adult stature. For the latter, low 
dose oxandrolone was given in late childhood with estrogen, replacement typically delayed 
until the age of 14 or 15 years to extend the growth period. In the 1980s the development of 
recombinant human growth hormone (rhGH) changed the approach to increasing height. 
Turner syndrome was the first non-growth hormone-deficient condition in which the 
efficacy of rhGH was formally examined with randomized, controlled trials, and treatment 
was subsequently implemented as standard of care. Concurrently, the endocrine community 
began to deal with Turner syndrome more comprehensively. In the last 10–15 years, the 
emphasis of care shifted from dealing with the growth deficit, to applying advanced 
reproductive technology allowing live births, detecting and dealing with potential 
catastrophic cardiovascular disease (CVD), and addressing long-term health issues. It is now 
apparent that there is significant excess mortality in adult women with Turner syndrome, 
half of which is attributed to CVD. While CVD complications typically manifest during 
adult life, the problems begin during childhood, and must be addressed first by pediatric 
endocrinologists and cardiologists, then transitioned to adult practitioners. Smooth transition 
from pediatric to adult care is key to maintaining appropriate surveillance for comorbidities 
and optimal delivery of health care to women with Turner syndrome. The challenge now is 
to incorporate the new approaches to clinical care, to deal with the problems of transition, 
and to apply the most modern genetic methodologies that will address important health 
concerns in this population.
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Turner syndrome guidelines revisited. Carolyn Bondy, MS, MD—Since the 2007 
NIH Consensus Conference on guidelines on diagnosis and care for patients with Turner 
syndrome, [Bondy and Turner Syndrome Study, 2007] major developments in genetic 
diagnosis and cardiac imaging technologies have emerged. Commercially marketed genomic 
testing kits claim detection of Turner syndrome and other chromosomal anomalies 
prenatally as early as 10 weeks of pregnancy. However, the American College of Obstetrics 
and Gynecology requires confirmation by standard prenatal cytogenetic testing [Genetics 
2013]. The concern is that parental distress will lead to ill-informed terminations of early 
pregnancies. Current American College of Medical Genetics guidelines for diagnosis of 
Turner syndrome requires standard cytogenetic karyotype analysis. DNA-sequencing or 
DNA-array analyses from spot samples of saliva or blood suggest less laborious tests may 
be useful [Gregg et al., 2013]. More study is needed to demonstrate the reliability of these 
newer techniques. Advances in cardiovascular magnetic resonance imaging (cMRI) show 
that up to 25% of significant aortic abnormalities in Turner syndrome are not detectable by 
routine echocardiography. Thus, cMRI for all girls with Turner syndrome at an early age or 
at the time of diagnosis in older patients should be considered. Individuals who have aortic 
disease are at risk for complications, including aortic valve dysfunction and thoracic aortic 
dissection or rupture [Carlson et al., 2012]. It will be important to define which patients 
require close monitoring and counseling regarding safe levels of activity or attempting 
pregnancy. Treating toddlers with growth hormone (rhGH) may prevent growth from falling 
below the normal range and potentially reduce the duration and dosage of rhGH treatment. 
Treatment at a younger age may be important to optimize long-term height outcome. 
Because most of the data supporting the efficacy and safety of rhGH treatment in Turner 
syndrome derive from girls treated from approximately age 7, earlier treatment and/or longer 
duration need validation by additional controlled studies. Another area of active study is the 
timing of initiation of estrogen treatment, and the value of transdermal application of 17-
beta estradiol versus varied forms of oral estrogen treatment.
Barriers to health care access for patients with Turner syndrome. David E. 
Sandberg, PhD—Turner syndrome is well described from a clinical standpoint. Clinical 
practice guidelines provide guidance regarding details of screening for problems at the time 
of diagnosis as well as the need for ongoing monitoring. The distinction between what is 
recommended and what is achieved is nowhere more apparent than in the coordination of 
the multiple specialty services involved in caring for those affected with Turner syndrome 
and their families. The barriers to delivering evidence-based comprehensive and integrated 
health care services can be classified as intra-institutional, extra-institutional, and cross-
institutional (Table I). At the institutional level, integration, coordination, and continuity of 
care loom large as barriers to optimal health outcomes. Providers in an interdisciplinary 
team meet regularly to discuss and collaboratively set treatment goals for the patients and 
jointly carry out the treatment plans. A key barrier to interdisciplinary care is the lack of 
availability of certain specialties, in particular, behavioral health, either because of scarcity 
of this resource at the institution, or because of limited reimbursement. Extra-institutional 
barriers include factors such as the geographic location of interdisciplinary health care teams 
for Turner syndrome, generally found in tertiary care centers. Insurance coverage and its 
cost represent additional potential barriers to interdisciplinary team care. Although the U.S. 
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Patient Protection and Affordable Care Act of 2010 expanded health care coverage and 
prohibited the practice of excluding coverage for those with preexisting conditions, 
insurance providers may still restrict delivery of services to preferred in-network providers 
and facilities that are unable to assemble the expertise required for optimal care for patients 
with complex health care needs such as those with Turner syndrome. Furthermore, effective 
implementation of transition of health care services from pediatric to adult providers 
remains elusive.
Finally, “cross-institutional” barriers in this context refer to limited standardization in the 
process of diagnosis, description of the Turner syndrome phenotype and variability in 
clinical management practices across health care centers. Electronic health records offer the 
opportunity to enhance the process of standardization and reduce variability in practice. 
Movement in this direction not only provides the possibility to improve the quality of care 
and outcomes for the individual patient, but the standardization that would flow from such 
initiatives could also serve as a scalable platform for clinical research involving a national 
network of clinical teams focused on Turner syndrome.
Summary of advocacy panel poll of members of the Turner syndrome 
community, Gary A. Lorigan PhD—A survey was sent out to 4,147 members of the 
Turner syndrome community. The purpose of the survey was to answer the following three 
questions:
1. What are the major health and well-being issues facing girls and women living with 
Turner syndrome?
2. What is needed to ensure care for patients with Turner syndrome through the 
transition period into adulthood?
3. What are the barriers to better health and wellness for people living with Turner 
syndrome?
The survey's structure separated respondents into two categories: women with Turner 
syndrome and adults caring for girls with Turner syndrome under the age of 18. There were 
385 responses from women 18–70+ years of age, and 417 responses from parents or 
guardians of girls with Turner syndrome under age 18. The four major medical concerns 
overall were endocrine, growth rate (for those under 18 years), cardiovascular, and hearing/
ear. The major psychological/social issues were age-dependent, but included short stature, 
anxiety, educational challenges, poor motor skills, attention deficit, sexual function, low 
self-esteem, and social interactions. Other important issues included employment 
challenges, driving, and depression. The major health maintenance issues were lack of 
knowledgeable providers for needs of individuals with Turner syndrome, oversight of all 
healthcare components, and online access to resources for patients with Turner syndrome. 
For access to clinical care, the majority of respondents want a clinic no more than three 
hours away, which is a significant problem given the lack of existing centers or clinics for 
Turner syndrome across the U.S. Forty percent of the women with Turner syndrome 
surveyed wanted access to a specialized clinic/center, and 35% said that they wanted a 
primary care physician who was knowledgeable in health concerns related to Turner 
syndrome. About 50% of adult respondents said they would be willing to continue their care 
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in a pediatric facility if it ensured that care would come from a knowledgeable provider. The 
cost of health care and insurance were of concern to the majority of respondents. The 
surveys indicate the need for more research into issues and concerns related to Turner 
syndrome, better oversight of all aspects of healthcare, and the need for easy online access to 
information and resources for patients living with Turner syndrome.
Synopsis from the professional panel discussions regarding regional Turner 
syndrome resource centers. Philippe Backeljauw MD—A recent survey on the 
status of Turner syndrome clinics in the U.S. revealed that approximately 20–25 healthcare 
institutions identified the existence of such a subspecialty clinic. The size and length of time 
these clinics have been in existence varies considerably. Some of the institutions support a 
true Turner syndrome center and are able to provide state-of-the-art care through the 
involvement of multiple specialties, as well as via the interaction with patient support 
groups. Only a few are also able to care for adults with Turner syndrome. The major health 
and well-being issues and challenges currently facing girls and women with Turner 
syndrome from a care provider perspective include:
1. Proper transition of pediatric patients to adult care;
2. Education regarding co-morbidities and preparedness for adult care/life for patients 
with Turner syndrome, including reproductive issues;
3. Access to appropriate developmental, psychological and psychiatric evaluation and 
therapy;
4. Obtaining adequate health insurance coverage.
Several barriers to improving health and wellness for patients with Turner syndrome have 
been identified:
1. Lack of follow-up care;
2. Lack of coordination of subspecialty care;
3. Difficulty in identifying knowledgeable (adult) providers;
4. Lack of uniform criteria for lifelong screening and care for patients with Turner 
syndrome.
The professional panel envisions several regional, comprehensive clinical centers. This 
could potentially lead to an integrated national TS care network. An educational component 
could be part of the TS clinic activities with patients and their families and local TS support 
groups collaborating to increase TS awareness and provide counseling. TS research could be 
integrated into a TRN, through which the smaller TS clinics could feed into larger TS 
resource centers. Quality improvement projects could be developed, as well as novel pilot 
research studies and multi-center studies.
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Turner Science: from Genotype to Phenotype
Estrogen Replacement in Adolescents With Turner Syndrome. Nelly Mauras, MD
The proper timing, dose and more recently, route of estrogen replacement in hypogonadal 
girls with Turner syndrome have been better characterized in recent studies. Although 
historically, conjugated equine estrogens (CEE) had been the typical method of estrogen 
replacement for patients with Turner syndrome and other hypogonadal states in the U.S., 
CEE contains over 100 forms of estrogens of different potencies and biological activity. 
Estradiol (17βE2) is the most physiological estrogen available for replacement as it is 
identical to the product of the intact gonad. It also has the advantage that it can be accurately 
measured in plasma. Micronized 17βE2 should be the preferred choice for feminizing girls 
with different forms of hypogonadism. Most studies of the metabolic effects of the different 
routes of estrogen administration have used different types of estrogen, making comparisons 
across studies difficult. We recently studied the metabolic effects of the same form of 
estradiol, 17βE2 administered either orally or transdermally, in a group of 40 girls with 
Turner syndrome in whom we titrated the doses based on E2 concentrations obtained 
monthly, measured by liquid chromatography—mass spectroscopy. We aimed to achieve 
levels comparable to those of normally menstruating adolescents measured in the same 
assay in both groups. All subjects were cycled with progesterone monthly. After 12 months 
of treatment, there were no differences between the groups for E2 concentrations, body 
composition, lean body mass, adiposity, bone mass accrual or energy expenditure, LH/FSH 
suppression or lipid concentrations. IGF-I concentrations trended lower in the transdermal 
group, but still remained within normal range. However, there were considerable differences 
in the levels of estrone, estrone sulfate and total bioestrogen concentrations (measured using 
a recombinant cell bioassay), with levels much higher in the oral group, creating an 
unphysiologic estrogen milieu. Both estrone and estrone sulfate can be stored in the 
adipocyte and breast tissue and recycled back into E2 creating a reservoir of estrogen in the 
body. These results are important, given the compelling body of data that have accumulated 
on the increased thromboembolic effects of oral over transdermal estrogens in both post- and 
pre-menopausal women. Whether transdermal estrogen produces a greater accumulation of 
other estrogen metabolites that can cause DNA damage (genotoxic estrogens) awaits further 
study. We concluded that adolescent girls with Turner syndrome should be feminized at the 
normal physiologic time, preferably using transdermal 17βE2 which produces a more 
physiologic milieu. The therapeutic guidelines for estrogen replacement therapy in Turner 
syndrome need to be revised.
Early Abnormalities in Social, Attentional, and Working Memory Circuits in Infants With 
Turner Syndrome. Rebecca Knickmeyer, PhD
Adults and children with Turner syndrome differ from typical female individuals with 
46,XX karyotype in key components of neural circuits for social cognition and working 
memory. Specifically, imaging studies demonstrate reductions in somatosensory cortex and 
inferior parietal lobule, enlargement of the amygdalae and insular and orbitofrontal cortex, 
altered white matter microstructure and disrupted frontoparietal circuitry in women with 
Turner syndrome. Altered activation of the amygdala and caudate during cognitive tasks 
also has been reported. What is not known is when in development these relationships arise. 
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This knowledge gap is important, as it limits our ability to determine the appropriate type 
and timing of behavioral interventions and hormone therapies. Imaging of infants with 
Turner syndrome showed decreased gray matter volumes in parietal cortex and increased 
gray matter volumes in insular cortex when compared to female controls, consistent with 
findings in older children. This suggests a stable phenotype, with origins in the prenatal or 
early postnatal period. Infants with Turner syndrome did not exhibit widespread changes in 
white matter microstructure that have been reported in older children, suggesting that early 
interventions might prevent or ameliorate atypical white matter development in Turner 
syndrome. At 1 year of age, functional connectivity maps revealed reduced fronto-parietal 
connectivity in infants with Turner syndrome, and increased connectivity with the insula. At 
age 2, functional connectivity maps revealed a lack of typical connectivity between caudate 
and frontal lobe in infants with Turner syndrome. Extensive negative correlations with 
middle temporal gyrus were present in infants with Turner syndrome, but not in controls. 
Additional studies are needed to examine longitudinal changes in brain structure and 
function in Turner syndrome, relate clinical variables (such as genetic and hormonal 
variation) to brain development, and test whether individual variation in neuroimaging 
phenotypes predicts cognitive outcomes.
Genetic and Epigenetic Mechanisms Underlying Early Brain Development, Cognition, and 
Behavior in TS. David S. Hong, M.D
Significant concerns for parents and individuals with Turner syndrome are the potential 
cognitive issues associated with this condition. Neuropsychological, genetic and 
neuroimaging studies indicate that overall intelligence in Turner syndrome is within the 
normative range. However, specific cognitive sub-domains may represent areas of risk, 
including visuospatial skills, executive function, arithmetic and social cognition, while 
others may be relatively enhanced, such as verbal skills. Significant gaps in current 
understanding of cognitive aspects of Turner syndrome still remain, particularly in regard to 
the correlation between older neuropsychological findings and more recent genetic and 
neuroimaging data, as well as a clearer view of the trajectory of cognitive development in 
Turner syndrome over the lifespan. Recent studies may provide further insight into 
developmental issues related to Turner syndrome, including the first concrete evidence for 
aberrant longitudinal trajectories of neurodevelopment, confirming the critical need for 
using lifespan studies to better delineate dynamic changes in brain growth patterns across 
various stages of development. It is important to understand how these brain findings relate 
to long-term adaptive outcomes. Understanding the genotype-phenotype relationships 
between genes on the X chromosome and brain development is also important. Findings 
include evidence of imprinting, an epigenetic mechanism related to parental origin of 
genetic material. Girls who have 45,X karyotype with a paternally-derived X chromosome 
perform less well in the performance IQ domain relative to peers with a maternally-derived 
X chromosome, a finding which may reflect a neurobiological basis for observed cognitive 
differences between these two cohorts. Additionally, X chromosome “dosage” may have a 
specific effect on brain development, with the number of sex chromosomes linearly 
correlated to brain volumes in the temporal and parietal lobes. In totality, advances in 
neuroimaging and genetic technologies over the past decade have significant potential to 
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exponentially increase our understanding of cognition and neurodevelopment in Turner 
syndrome.
Genetic Basis of Bicuspid Aortic valve in Turner Syndrome. Siddharth K. Prakash, MD, 
PhD
Bicuspid aortic valve (BAV) is the most common congenital heart defect. BAV is caused by 
the failure of two or more cusps to separate during late stages of embryonic development. 
The prevalence of BAV is increased more than 30-fold in women with Turner syndrome, 
who are at greatly increased risk for acute aortic dissections. Girls and women with Turner 
syndrome require operations for significant left heart obstructive disease far more than those 
without the condition. We hypothesize that at least two genetic hits are required for 
susceptibility to aortic disease in Turner syndrome. The first hit may be a reduction in the 
dosage of X chromosome genes due to X chromosome structural variation in Turner 
syndrome. A second hit could be a common variant or a modifier allele that does not cause 
disease by itself but may interact with reduced X chromosome dosage to account for the 
prevalence of BAVs in women with Turner syndrome. To test our hypothesis, we performed 
a genome-wide association study in women with Turner syndrome comparing those with 
BAV to those with normal tricuspid aortic valves. We observed suggestive association peaks 
on chromosomes 4, 18, and 22, with a minimum P-value of 1 × 10−7. We also confirmed 
that BAV is strongly associated with the dosage, but not the genotypes of single nucleotide 
polymorphisms on the short arm of the X chromosome (Xp) and used breakpoint mapping to 
identify several new candidate Xp genes for BAV. These findings are consistent with our 
hypothesis that BAV may be caused by reduced X chromosome dosage in women with 
Turner syndrome, as well as men in the general population, and opens new avenues for BAV 
gene discovery.
Insights into Congenital and Ischemic Heart Disease From Studies in Turner Syndrome. 
Carolyn Bondy, MS, MD
Five hundred girls and women with rigorously established Turner syndrome karyotypes 
were examined with cardiac MRI as well as transthoracic ultrasound. These imaging studies 
show that approximately 50% of study subjects had an abnormal elongation of the transverse 
portion of the aortic arch (ETA). This anomaly is associated with a distinctive kink in the 
lesser curvature and bulbous dilation of the left subclavian artery origin in the region usually 
involved in aortic coarctation. The specific anatomic alterations of defective aortic valve and 
aortic coarctation were exclusively found among those with ETA. While the bicuspid aortic 
valve was found in 30% of the general study population, it was found in 60% of those with 
the ETA, suggesting that haploinsufficiency for unknown X/Y chromosomal gene(s) caused 
abnormal aortic arch development, which secondarily led to defective aortic valve 
development, and likely also to aortic coarctation, possibly due to severely abnormal blood 
flow patterns in the developing aortic arch. This possibility is supported by the finding of 
severe abnormalities of the transverse arch (interruption or tubular hypoplasia) in 45, X 
fetuses or newborns that succumbed to cardiovascular defect. Genetic studies of the 
congenital cardiovascular phenotype mapped the phenotype to the short arm of the X 
chromosome, telomeric to Xp.11.4 (and homologous gene(s) present on Yp). Congenital 
defects were equally prevalent in groups with a single X chromosome derived from the 
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mother or the father, indicating that genomic imprinting does not contribute to the risk for 
congenital cardiac defects in Turnersyndrome. We investigated deposits of calcium in the 
coronary arteries of groups monosomic for a maternal versus paternal X chromosome, and 
found that the coronary calcium was abundant in women with a maternal X (similar to age-
matched population men from the Framingham study) and totally absent from the coronaries 
of women with a paternal X, suggesting that the presence of a single maternal X 
chromosome is an independent risk factor for atherosclerotic coronary disease.
Genomic Approaches to Understanding Congenital Cardiac Anomalies in Congenital Heart 
Disease (CHD) in Turner Syndrome, Paul Kruszka, MD
Congenital heart disease occurs in almost half of girls and women with Turner syndrome 
and is a leading cause of morbidity and mortality. Bicuspid aortic valve occurs in over 30% 
of individuals with Turner syndrome and aortic coarctation occurs in approximately 12%. 
Aortic dissection, the most catastrophic anomaly, is increased more than 100-fold in Turner 
syndrome. Previous studies suggest that a genetic culprit is located on the short arm of the X 
chromosome (Xp); however, a single gene, or group of genes, causing CHD in Turner 
syndrome have yet to be found. The most popular hypothesis is that haploinsufficiency of 
the pseudoautosomal region (PAR1) genes or other genes on Xp that have homologues on 
the Y chromosome contribute to the cause of CHD. Unfortunately, an adequate animal 
model for CHD in Turner syndrome does not exist, as the XO mouse does not have heart 
defects.
Maximilian Muenke at the National Human Genome Research Institute, the National 
Institutes of Health (NIH) is conducting whole exome sequencing in girls and women with 
Turner syndrome in an effort to better understand the genetic and molecular underpinnings 
of cardiac disease in this condition. Additionally, new gene editing techniques and animal 
models of Turner syndrome are being developed to couple gene discovery in humans with 
functional analyses. This multidisciplinary approach to research in Turner syndrome is 
directed at developing mechanistic insights into CHD in the condtion and provides an 
avenue for the development of new diagnostic and therapeutic capabilities in the future.
Crossroads of Health Policy and Research: Roadmap Toward the TRN
Securing a National Turner Syndrome Program in an Era of Declining Federal Resources. 
David A. Cole, PhD
Building a robust TRN is a worthy goal, but one that will require substantial financial 
resources—resources in excess of those currently raised by the Turner Syndrome Society 
(TSSUS) and the Turner Syndrome Foundation (TSF) combined. The TRN will face 
challenges in the form of several key scientific and philanthropic trends: a) NIH and 
National Science Foundation grant making, especially for basic scientific investigation, is 
falling victim to federal budget cutting; b) corporate grant making is on the decline and 
increasingly tied to companies' marketing objectives; c) corporate and foundation grant 
makers are allocating fewer dollars for indirect cost recovery; d) the time required to apply 
for, and steward, institutional grants is increasing; and e) grant makers are fielding record 
numbers of applications and making smaller grants. One additional philanthropic trend, 
Backeljauw et al. Page 13
Am J Med Genet A. Author manuscript; available in PMC 2016 January 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
however, suggests another, more promising approach: substantial sums, allocated by 
individuals for philanthropy, are increasingly being channeled into private foundations and 
donor advised funds (DAFs). TSSUS and TSF should consider pooling their resources and 
investing in a major gifts fundraiser. The centrally coordinated resources of TSSUS/TSF 
could be directed toward the following activities: 1) leveraging existing ties to TSS/TSF 
supporters and members to identify, and build new relationships; 2) developing a major gifts 
“moves management” function within TSSUS/TSF to coordinate prospect identification, 
cultivation, applications, and gift/grant stewardship on a national level. This function would 
ensure that fundraising steps are centrally managed and communicated across the TRN 
network; 3) ensuring that TSSUS/TSF establish and maintain a major gifts focus on their 
common website, on social media, and in related communications collateral
Successful Models for Conceiving, Implementing, and Conducting Multi-Center Research. 
Victoria Pemberton, RNC, MS
Like other rare diseases, clinical care and research in Turner syndrome faces similar 
challenges related to the small number of affected individuals seen at any given institution; 
heterogeneity of care practices, and physicians' and patients' limited experiences of 
participating in research. Networks or “Collaboratories,” composed of multiple research 
centers, are likely necessary for the effective conduct of clinical research with adequate 
numbers of patients to meet sample size requirements. Key elements for a successful TRN 
were identified and include standardization of research procedures, multidisciplinary 
working relationships, shared learning regarding mistakes and successes, open access to 
researchers with important study proposals, integrating research with clinical care, and 
central monitoring and oversight. The TRN must nurture partnerships with patient advocacy 
groups as these groups serve as conduits for education among their members about the 
importance of research, they provide insight into potential study questions, highlighting 
those that are most critical to individuals with Turner syndrome, and they provide support 
and resources such as potential research participants, educational information, financial 
support, and political advocacy on behalf of the TRN. An effective infrastructure must 
consider leveraging funding opportunities with government agencies, pharmaceutical 
companies, foundations, advocacy groups and investigators with similar interests. An 
important mission for the TRN will be to discern the “extended opportunities” that can lead 
to therapies and interventions for both Turner syndrome and other populations.
TRN Roadmap Synopses (6 breakout sessions)
How the Turner resource network steering committee should be organized—
There should be a start-up steering committee, a working group tasked with calling for 
proposals, establishing criteria for the regional centers, and developing policies and 
procedures for how the network would operate. The group should be multidisciplinary and 
should also have family advocates/women living with Turner syndrome represented. The 
group must represent all of the diversity of opinions and thoughts within the TRN.
How will the TRN patient-powered registry be designed?—How the information 
will be accessed needs to be determined. The registry committee should include families and 
lay advocates alongside clinicians and researchers. This group will decide the areas of focus, 
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what important outcomes should be, the types of data that should be collected, and how the 
information will be used. The existing NHLBI-sponsored National Registry of Thoracic 
Aortic Aneurysms and Related Conditions (GenTAC) contains over 300 subjects with 
Turner syndrome for whom extensive cardiovascular data, both cross-sectional and 
longitudinal, have been collected [Kroner et al., 2011]. When the TRN registry incorporates 
the GenTAC Turner data it will be research ready. An application to the PCORI patient-
powered research network (PPRN) [Daugherty et al., 2014] is planned. Transparency 
regarding how the Turner database can be used for research purposes will be necessary. Key 
questions without necessarily supplying specific answers were posed: What kind of data 
beyond the GenTAC cardiovascular component will be collected—longitudinal or cross-
sectional, retrospective or prospective? What domains of data general health, genetics, 
phenotype, and demographics need to be included? Should the data be comprehensive, 
agnostic or hypothesis-driven? Will it serve as a resource to both “TRN investigators” and 
outside individuals or organizations? What areas of data will be collected in a standardized 
fashion? Possibilities include: endocrine including reproductive endocrine, cardiovascular, 
genetics, and neurobiological, including cognition? Will the coordinating center serve as 
bio-repository of genetic data, imaging data? Will the coordinating center serve as bio-
repository of genetic data, imaging data? A group volunteered to further consider the 
question going forward.
How will the Turner resource network be funded?—Without the aligned support of 
the three major advocacy groups, the Turner Syndrome Society of the United States, the 
Turner Syndrome Foundation and the Turner Syndrome Global Alliance, the TRN will not 
succeed. It is through the membership of these organizations that avenues for philanthropic 
support will become apparent. Perhaps needed services, informatics/database support, can be 
obtained by soliciting contributions from a large group of people, and especially from an 
online community (“crowdsourcing”) may be an option. Employing a professional skilled in 
philanthropic activities will be necessary. Funding opportunities from all potentially 
receptive health organizations will be explored. In particular, requests for applications to the 
Patient Centered Outcomes Research Initiative (PCORI) will be primarily considered.
What is the ideal regional resource center?—The focus should be the regional 
Turner syndrome clinic. The key to success for these clinics is coordination of care for the 
individual living with Turner syndrome. A successful clinic will be a platform through 
which research can be performed. The clinic will require designated standards and some 
measures to evaluate each clinic's success. Primary care coordination will require at the very 
least, cardiology, endocrinology, and neuro-developmental expertise. The action item is to 
publish the current matrix of 25 Turner regional centers collated by Dr. Angela Lin, and to 
develop a working group to establish the criteria for designation as a regional resource 
center.
Which Turner syndrome guidelines need to be revisited?—The guidelines overall 
should be updated. Consideration should be given to publishing guidelines on a specific 
subtopic as a way of tackling the larger issue of guidelines updates. Consideration should be 
given to taking an age-related life span approach (fetus, infant, child, adolescent, and adult). 
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Lay versions of the guidelines should be created. There are a number of pressing specific 
questions: Which sex steroid replacement therapies and the timing, dosage and other issues 
of sex steroid therapy need to be clarified? Turner syndrome diagnosis options and their 
utilization/timing need to be defined (karyotype vs. microarray, newborn screening).
Timing and need for other medical screening tests need to be clarified. The indications for 
echocardiography versus MRI for cardiovascular disease are unclear. Dosing and timing of 
rhGH therapy recommendations should be studied further. What are the indications, 
contraindications, and relative contraindications for pregnancy? What screening tests are 
needed prior to pregnancy? A pregnancy consent form should be considered as a way to 
precipitate a thorough discussion about potential risks. Guidelines for fertility preservation 
need to be established. Indications for cognitive assessment and their relative value are 
unclear.
How will the Turner resource network research project be reviewed?—Funds 
within the TRN will be available for research projects. In addition, investigators with their 
own funds will wish to take advantage of TRN resources for Turner syndrome-related 
projects. The major factor determining research priorities overall will be the best science 
that meets the priorities as set by the TRN scientific advisory committee.
Conclusions
Morbidity and mortality in Turner syndrome is unacceptably high. The TRN needs to help 
find ways to improve health policy and health care delivery for girls and women living with 
Turner syndrome by: 1) creating nationally coordinated regional resource centers linked by a 
patient-powered registry; 2) conducting high quality outcomes-based clinical research; and 
3) supporting basic Turner science programs. The research community in general needs to 
step up in terms of efforts to understand sex-chromosome biology, its deep biology in all of 
its complexity, so that we can better understand the clinical and personal ramifications of 
living with Turner syndrome. We must also elucidate the role of the X chromosome in 
common disease susceptibility in the general population. A concerted effort by the NIH, 
national medical/scientific foundations and societies, as well as the pharmaceutical industry 
is necessary to bring the sex chromosomes back to the forefront of research. The TRN can 
encourage and promote this process by engaging in research in Turner syndrome.
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Fig. 1. Cumulative risk of death from all causes and from circulatory disease observed in the 
cohort of patients with Turner syndrome and risk expected based on general population rates 
for females (reproduced with permission Schoemaker and other 2008)
Backeljauw et al. Page 19
Am J Med Genet A. Author manuscript; available in PMC 2016 January 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Backeljauw et al. Page 20
Table I
Selected Barriers to Full Implementation of Turner Syndrome Clinical Practice 
Guidelines
Internal External Cross-institutional
integration/coordination location standardization
“team” care cost/insurance practice guidelines
behavioral health transition
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